These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 9297557)

  • 1. Synovial fluid levels of tumor necrosis factor-alpha in the inflamed rat knee: modulation by dexamethasone and inhibitors of matrix metalloproteinase and phosphodiesterase.
    Singh HN; Blancuzzi V; Greenwood S; Skiles JW; O'Byrne EM
    Inflamm Res; 1997 Aug; 46 Suppl 2():S153-4. PubMed ID: 9297557
    [No Abstract]   [Full Text] [Related]  

  • 2. Anti-inflammatory activity of phosphodiesterase (PDE)-IV inhibitors in acute and chronic models of inflammation.
    Sekut L; Yarnall D; Stimpson SA; Noel LS; Bateman-Fite R; Clark RL; Brackeen MF; Menius JA; Connolly KM
    Clin Exp Immunol; 1995 Apr; 100(1):126-32. PubMed ID: 7697910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppression of lipopolysaccharide-induced tumor necrosis factor-alpha generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: interaction with stimulants of adenylyl cyclase.
    Seldon PM; Barnes PJ; Meja K; Giembycz MA
    Mol Pharmacol; 1995 Oct; 48(4):747-57. PubMed ID: 7476903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preventive but not therapeutic application of Rolipram ameliorates experimental autoimmune encephalomyelitis in Lewis rats.
    Jung S; Zielasek J; Köllner G; Donhauser T; Toyka K; Hartung HP
    J Neuroimmunol; 1996 Aug; 68(1-2):1-11. PubMed ID: 8784254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of cAMP-dependent inhibition of LPS-induced TNF alpha production by rolipram, a specific phosphodiesterase IV (PDE IV) inhibitor.
    Prabhakar U; Lipshutz D; Bartus JO; Slivjak MJ; Smith EF; Lee JC; Esser KM
    Int J Immunopharmacol; 1994 Oct; 16(10):805-16. PubMed ID: 7843852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The specific type IV phosphodiesterase inhibitor rolipram differentially regulates the proinflammatory mediators TNF-alpha and nitric oxide.
    Greten TF; Eigler A; Sinha B; Moeller J; Endres S
    Int J Immunopharmacol; 1995 Jul; 17(7):605-10. PubMed ID: 8586489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclic nucleotide phosphodiesterase type IV participates in the regulation of IL-10 and in the subsequent inhibition of TNF-alpha and IL-6 release by endotoxin-stimulated macrophages.
    Kambayashi T; Jacob CO; Zhou D; Mazurek N; Fong M; Strassmann G
    J Immunol; 1995 Nov; 155(10):4909-16. PubMed ID: 7594495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of rolipram in a murine model of acute inflammation: comparison with the corticoid dexamethasone.
    Klemm P; Harris HJ; Perretti M
    Eur J Pharmacol; 1995 Jul; 281(1):69-74. PubMed ID: 8566119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis.
    Sommer N; Löschmann PA; Northoff GH; Weller M; Steinbrecher A; Steinbach JP; Lichtenfels R; Meyermann R; Riethmüller A; Fontana A
    Nat Med; 1995 Mar; 1(3):244-8. PubMed ID: 7585041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased peripheral benzodiazepine binding sites and pentraxin 3 expression in the spinal cord during EAE: relation to inflammatory cytokines and modulation by dexamethasone and rolipram.
    Agnello D; Carvelli L; Muzio V; Villa P; Bottazzi B; Polentarutti N; Mennini T; Mantovani A; Ghezzi P
    J Neuroimmunol; 2000 Sep; 109(2):105-11. PubMed ID: 10996212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Airway relaxant and anti-inflammatory properties of a PDE4 inhibitor with low affinity for the high-affinity rolipram binding site.
    Martin C; Göggel R; Dal Piaz V; Vergelli C; Giovannoni P; Ernst M; Uhlig S
    Naunyn Schmiedebergs Arch Pharmacol; 2002 Apr; 365(4):284-9. PubMed ID: 11919652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of rolipram on cyclic AMP levels in alveolar macrophages and lipopolysaccharide-induced inflammation in mouse lung.
    Gonçalves de Moraes VL; Singer M; Vargaftig BB; Chignard M
    Br J Pharmacol; 1998 Feb; 123(4):631-6. PubMed ID: 9517381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNF alpha generation from human monocytes by interacting with a 'low-affinity' phosphodiesterase 4 conformer.
    Souness JE; Griffin M; Maslen C; Ebsworth K; Scott LC; Pollock K; Palfreyman MN; Karlsson JA
    Br J Pharmacol; 1996 Jun; 118(3):649-58. PubMed ID: 8762090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The influence of phosphodiesterase inhibitor, rolipram, on hemodynamics in lipopolysaccharide-treated rats.
    Dutta P; Ryan DE; Tabrizchi R
    Jpn J Pharmacol; 2001 Mar; 85(3):241-9. PubMed ID: 11325016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amelioration of collagen II-induced arthritis in rats by the type IV phosphodiesterase inhibitor Rolipram.
    Nyman U; Müssener A; Larsson E; Lorentzen J; Klareskog L
    Clin Exp Immunol; 1997 Jun; 108(3):415-9. PubMed ID: 9182885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential regulation of rheumatoid synovial cell interleukin-12 production by tumor necrosis factor alpha and CD40 signals.
    Kitagawa M; Mitsui H; Nakamura H; Yoshino S; Miyakawa S; Ochiai N; Onobori M; Suzuki H; Sumida T
    Arthritis Rheum; 1999 Sep; 42(9):1917-26. PubMed ID: 10513808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The specific type IV phosphodiesterase inhibitor rolipram suppresses tumor necrosis factor-alpha production by human mononuclear cells.
    Semmler J; Wachtel H; Endres S
    Int J Immunopharmacol; 1993 Apr; 15(3):409-13. PubMed ID: 8505151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of isoenzyme selective phosphodiesterase inhibitors on bacterial lipopolysaccharide-induced bronchial hyperreactivity in guinea pigs.
    Uno T; Tanaka H; Nagai H
    Gen Pharmacol; 1998 Feb; 30(2):167-73. PubMed ID: 9502170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of tumour necrosis factor production by adrenal hormones in vivo: insights into the antiinflammatory activity of rolipram.
    Pettipher ER; Labasi JM; Salter ED; Stam EJ; Cheng JB; Griffiths RJ
    Br J Pharmacol; 1996 Apr; 117(7):1530-4. PubMed ID: 8730750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rolipram, a specific type IV phosphodiesterase inhibitor, is a potent inhibitor of HIV-1 replication.
    Angel JB; Saget BM; Walsh SP; Greten TF; Dinarello CA; Skolnik PR; Endres S
    AIDS; 1995 Oct; 9(10):1137-44. PubMed ID: 8519449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.